title: CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response.
authors.affiliation: Cambridge, MA
authors.forename: Ellen
authors.initials: E
authors.lastname: Cahir-McFarland
authors.affiliation: Cambridge, MA
authors.forename: Richard M
authors.initials: RM
authors.lastname: Ransohoff
authors.affiliation: Cambridge, MA
authors.forename: Linda
authors.initials: L
authors.lastname: Lieberman
authors.affiliation: Cambridge, MA
authors.forename: Tatiana
authors.initials: T
authors.lastname: Plavina